James M. Foran

Also affiliated with Jacksonville College, WinnMed, Mayo Clinic in Florida

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies”.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3706

N/A

4.4DataRank · unranked

198 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Blood Advances(2022)10.1182/bloodadvances.2022008625

N/A

0.839DataRank · unranked

19 citations

Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock +35 more

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9

N/A

0.783DataRank · unranked

184 citations

Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji +35 more

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study

Blood Advances(2023)10.1182/bloodadvances.2022009000

N/A

0.697DataRank · unranked

16 citations

Donnie Hebert, Cecilia Lee, Dana E. Rollison, Nancy Gillis, Rami S. Komrokji +15 more

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

American Journal of Hematology(2021)10.1002/ajh.26186

N/A

0.631DataRank · unranked

66 citations

Paola Guglielmelli, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Mark R. Litzow +11 more

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood(2024)10.1182/blood.2024024756

N/A

0.593DataRank · unranked

51 citations

Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Geyer, Anand Patel +39 more

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies

Blood Advances(2023)10.1182/bloodadvances.2023010061

N/A

0.554DataRank · unranked

12 citations

Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M. Foran, Jane Jijun Liu +19 more

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

American Journal of Hematology(2021)10.1002/ajh.26417

N/A

0.546DataRank · unranked

37 citations

Marina Konopleva, Mrinal M. Patnaik, Elias Jabbour, Courtney D. DiNardo, Aref Al‐Kali +7 more

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Blood Advances(2020)10.1182/bloodadvances.2019001266

N/A

0.542DataRank · unranked

36 citations

Rajneesh Nath, Jan Černý, Hai-Lin Wang, Mei-Jie Zhang, Hisham Abdel‐Azim +80 more

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm

Haematologica(2022)10.3324/haematol.2022.282019

N/A

0.449DataRank · unranked

19 citations

Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al-Kali, Mrinal M. Patnaik +13 more

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis

Cancer(2023)10.1002/cncr.34807

N/A

0.400DataRank · unranked

8 citations

Zhuoxin Sun, Catherine Lai, Hugo F. Fernández, Larry D. Cripe, Rhett P. Ketterling +11 more

A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.09.020

N/A

0.312DataRank · unranked

7 citations

Tamer Othman, Rima M. Saliba, Yenny Alejandra Moreno Vanegas, Razan Mohty, Celina Ledesma +18 more

Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia

American Journal of Hematology(2020)10.1002/ajh.25729

N/A

0.292DataRank · unranked

6 citations

Ryan A. Knudson, Kathryn E. Pearce, Reid G. Meyer, Beth A. Pitel, Jess F. Peterson +23 more

Advancing drug development in myelodysplastic syndromes

Blood Advances(2024)10.1182/bloodadvances.2024014865

N/A

0DataRank · unranked

12 citations

Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo +17 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more

Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2023)10.1158/1078-0432.c.6531017.v1

N/A

0DataRank · unranked

0 citations

Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas +21 more